Elizabeth Lee

12PUBLICATIONS
67CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)HaematologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Mar 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial.

Rebecca L Porter, Yinglu Zhou, Nebiyat Eskndir

|Jan 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.

Ezra Y Rosen, Timothy A Yap, Elisa Fontana

|Dec 03, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.

Panagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson

|Jul 24, 2025
Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors.

Ian M Silverman, Joseph D Schonhoft, Benjamin Herzberg

|Apr 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.

Panagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee

|Apr 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.

Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee

Pageof 2

Frequent Collaborators

7 joint publications

Panagiotis A Konstantinopoulos

6 joint publications

Madeline Polak

4 joint publications

Timothy A Yap

3 joint publications

David L Kolin